{"schema_version":"secwatch.filing_event.v1","accession":"0001528287-22-000026","form_type":"8-K","ticker":"NPCE","cik":"0001528287","company_name":"NeuroPace Inc","filed_at":"2022-11-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.030649+00:00","generated_at":"2026-06-22T03:32:13.306060+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"NeuroPace Q3 revenue $11.2M (+8% YoY); lifts FY revenue guidance to $44.5-45.5M","bullets":["Initial implant revenue $9.2M (+18% YoY); replacement revenue $1.9M vs $2.5M prior year.","Net loss $11.8M vs $8.1M prior year; operating expenses $18.2M vs $13.8M.","Cash and equivalents $85.4M, down from $92.4M at June 30; long-term debt $52.0M.","Gross margin 71% vs 73% due to short-term supply chain disruption, now resolved.","Initiated distribution of DIXI Medical stereo EEG electrodes on Oct 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001528287-22-000026","json":"https://secwatch.observer/filing/0001528287-22-000026.json","markdown":"https://secwatch.observer/filing/0001528287-22-000026.md","text":"https://secwatch.observer/filing/0001528287-22-000026.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/0001528287-22-000026-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/npce-20221108.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T03:32:13.306060+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8f60e9d5623cd4321af4a4e8fcccf542a4e7b806","claim":"NeuroPace Inc reported the quarter ending September 30, 2022 results: revenue $11.2 million, net income $11.8 million. Guidance raised.","evidence_excerpt":"the lives of people suffering from epilepsy, today reported financial results for the quarter ending September 30, 2022. Recent Highlights • Achieved total revenue of $11.2 million for the third quarter of 2022, representing growth of 8% compared to the third quarter of 2021 and 9% compared to the second quarter of 2022 • Achieved initial implant revenue of","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1528287/000152828722000026/0001528287-22-000026-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ending September 30, 2022"},{"label":"Revenue","value":"$11.2 million"},{"label":"Net income","value":"$11.8 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}